Anthony Wong, MD, PhD
Associate Professor
Radiation Oncology
School of Medicine

My research interests involve using new technologies, such as advanced imaging and genomic analysis, to improve radiation therapy for genitourinary malignancies. For example, in collaboration with the department of radiology, I am utilizing PSMA PET to map patterns of prostate cancer progression and relapse in the newly diagnosed and post-treatment settings. I am also investigating the use of HDR prostate brachytherapy in technically challenging scenarios, including patients with a prior history of transurethral resection of the prostate and patients who previously received pelvic radiation.

With regards to ongoing clinical trials, I am the radiation oncology site primary investigator for the UCSF institutional clinical trial investigating prostate SBRT and immunotherapy for newly diagnosed oligometastatic prostate cancer (CC#16703). I am the site PI for the FORMULA-509 trial (CC#18551), a multicenter randomized trial evaluating the use of apalutamide and abiraterone during post-prostatectomy salvage radiation therapy for prostate cancer patients with high-risk features. I am the site PI for NRG Oncology RTOG 3506 clinical trial evaluating the use of enzalutamide in patients during post-prostatectomy salvage radiation therapy for prostate cancer patients with high-risk features. In collaboration with UCSF and SFVA pathology departments, I am investigating the genomic landscape of variant histology prostate cancers in the interest of developing novel therapeutics.

I am interested in expanding the use of ablative radiation techniques. In collaboration with colleagues in the department of cardiology, I am working to bring a stereotactic body radiation therapy program for refractory ventricular arrhythmias to UCSF.

• Addition of Enzalutamide to Leuprolide and Definitive Radiation Therapy Is Tolerable and Effective in High-Risk Localized or Regional Nonmetastatic Prostate Cancer: Results From a Phase 2 Trial.
  Advances in radiation oncology 2022 Shee K, de la Calle CM, Chang AJ, Wong AC, Feng FY, Gottschalk AR, Carroll PR, Nguyen HG
• APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer.
  Frontiers in oncology 2022 Natesan D, Zhang L, Martell HJ, Jindal T, Devine P, Stohr B, Espinosa-Mendez C, Grenert J, Van Ziffle J, Joseph N, Umetsu S, Onodera C, Turski M, Chan E, Desai A, Aggarwal R, Wong A, Porten S, Chou J,…
• Safety of accelerated hypofractionated whole pelvis radiation therapy prior to high dose rate brachytherapy or stereotactic body radiation therapy prostate boost.
  Radiation oncology (London, England) 2022 Phuong C, Chan JW, Ni L, Wall P, Mohamad O, Wong AC, Hsu IC, Chang AJ
• Molecular risk classifier score and biochemical recurrence risk are associated with cribriform pattern type in Gleason 3+4=7 prostate cancer.
  Investigative and clinical urology 2022 Greenland NY, Cooperberg MR, Wong AC, Chan E, Carroll PR, Simko JP, Stohr BA
• Salvage High-Dose-Rate Brachytherapy for Recurrent Prostate Cancer After Definitive Radiation.
  Practical radiation oncology 2021 Wu SY, Wong AC, Shinohara K, Roach M, Cunha JAM, Valdes G, Hsu IC
• TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor.
  Journal for immunotherapy of cancer 2021 de Kouchkovsky I, Zhang L, Philip EJ, Wright F, Kim DM, Natesan D, Kwon D, Ho H, Ho S, Chan E, Porten SP, Wong AC, Desai A, Huang FW, Chou J, Oh DY, Pruthi RS, Fong L, Small EJ, Friedlander TW, …
• Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer.
  European urology 2021 Chu CE, Alshalalfa M, Sjöström M, Zhao SG, Liu Y, Chou J, Herlemann A, Mahal B, Kishan AU, Spratt DE, Cooperberg M, Small E, Wong A, Porten S, Hope TA, Ross AE, Davicioni E, Nguyen P, Karnes RJ, …
• Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate.
  JCO precision oncology 2020 Hall WA, Fishbane N, Liu Y, Xu MJ, Davicioni E, Mahal BA, Den RB, Dess RT, Jackson WC, Wong AC, Schaeffer EM, Karnes RJ, Carroll PR, Cooperberg MR, Bismar TA, Kim HL, Klein EA, Davis JW, Ross AE, …
• A Virion-Based Assay for Glycoprotein Thermostability Reveals Key Determinants of Filovirus Entry and Its Inhibition.
  Journal of virology 2020 Bortz RH, Wong AC, Grodus MG, Recht HS, Pulanco MC, Lasso G, Anthony SJ, Mittler E, Jangra RK, Chandran K
• NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer.
  International journal of radiation oncology, biology, physics 2020 Hall WA, Paulson E, Davis BJ, Spratt DE, Morgan TM, Dearnaley D, Tree AC, Efstathiou JA, Harisinghani M, Jani AB, Buyyounouski MK, Pisansky TM, Tran PT, Karnes RJ, Chen RC, Cury FL, Michalski JM, …
• Noninvasive ventricular tachycardia ablation: Should we apply the accelerator or the brake?
  Heart rhythm 2020 Dewland TA, Wong AC, Gerstenfeld EP
• Histological features and prognostic significance of treatment effect in lymph node metastasis in head and neck squamous cell carcinoma.
  Histopathology 2018 Scherpelz KP, Wong AC, Lingen MW, Taxy JB, Cipriani NA
• Late toxicity after post-prostatectomy intensity modulated radiation therapy: Evaluating normal-tissue sparing guidelines.
  Advances in radiation oncology 2018 Akthar AS, Wong AC, Parekh AD, Hubert G, Son CH, Pelizzari CA, Liauw SL
• PMRT: Please Mind Randomized Trials.
  International journal of radiation oncology, biology, physics 2017 Wong AC, Chmura SJ
• A feasibility study of 2-mm bolus for postmastectomy radiation therapy.
  Practical radiation oncology 2016 Das LC, Golden DW, Perevalova E, Wong AC, De Nardo K, Stepaniak C, Joyce DS, McCabe BP, Hasan Y, Chmura SJ, McCall A
• Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT).
  Cancer 2016 Wong AC, Watson SP, Pitroda SP, Son CH, Das LC, Stack ME, Uppal A, Oshima G, Khodarev NN, Salama JK, Weichselbaum RR, Chmura SJ
• Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs.
  Oncotarget 2016 Ranoa DR, Parekh AD, Pitroda SP, Huang X, Darga T, Wong AC, Huang L, Andrade J, Staley JP, Satoh T, Akira S, Weichselbaum RR, Khodarev NN
• Physicians' beliefs about the benefits and risks of adjuvant therapies for stage II and stage III colorectal cancer.
  Journal of oncology practice 2014 Wong AC, Stock S, Schrag D, Kahn KL, Salz T, Charlton ME, Rogers SO, Goodman KA, Keating NL
• Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation.
  PloS one 2013 Fang DD, Zhang CC, Gu Y, Jani JP, Cao J, Tsaparikos K, Yuan J, Thiel M, Jackson-Fisher A, Zong Q, Lappin PB, Hayashi T, Schwab RB, Wong A, John-Baptiste A, Bagrodia S, Los G, Bender S, Christensen J, …
• Contrast agents for quantitative microCT of lung tumors in mice.
  Comparative medicine 2013 Lalwani K, Giddabasappa A, Li D, Olson P, Simmons B, Shojaei F, Van Arsdale T, Christensen J, Jackson-Fisher A, Wong A, Lappin PB, Eswaraka J
• Biomarker and pharmacologic evaluation of the γ-secretase inhibitor PF-03084014 in breast cancer models.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Zhang CC, Pavlicek A, Zhang Q, Lira ME, Painter CL, Yan Z, Zheng X, Lee NV, Ozeck M, Qiu M, Zong Q, Lappin PB, Wong A, Rejto PA, Smeal T, Christensen JG
• Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice.
  Cancer chemotherapy and pharmacology 2012 Simmons BH, Lee JH, Lalwani K, Giddabasappa A, Snider BA, Wong A, Lappin PB, Eswaraka J, Kan JL, Christensen JG, Shojaei F
• Structural basis for differential neutralization of ebolaviruses.
  Viruses 2012 Bale S, Dias JM, Fusco ML, Hashiguchi T, Wong AC, Liu T, Keuhne AI, Li S, Woods VL, Chandran K, Dye JM, Saphire EO
• [(18)F]FLT-PET imaging does not always "light up" proliferating tumor cells.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Zhang CC, Yan Z, Li W, Kuszpit K, Painter CL, Zhang Q, Lappin PB, Nichols T, Lira ME, Affolter T, Fahey NR, Cullinane C, Spilker M, Zasadny K, O'Brien P, Buckman D, Wong A, Christensen JG
• A shared structural solution for neutralizing ebolaviruses.
  Nature structural & molecular biology 2011 Dias JM, Kuehne AI, Abelson DM, Bale S, Wong AC, Halfmann P, Muhammad MA, Fusco ML, Zak SE, Kang E, Kawaoka Y, Chandran K, Dye JM, Saphire EO
• Ebola virus entry requires the cholesterol transporter Niemann-Pick C1.
  Nature 2011 Carette JE, Raaben M, Wong AC, Herbert AS, Obernosterer G, Mulherkar N, Kuehne AI, Kranzusch PJ, Griffin AM, Ruthel G, Dal Cin P, Dye JM, Whelan SP, Chandran K, Brummelkamp TR
• HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors.
  Cancer research 2010 Shojaei F, Lee JH, Simmons BH, Wong A, Esparza CO, Plumlee PA, Feng J, Stewart AE, Hu-Lowe DD, Christensen JG
• Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design.
  Molecular cancer therapeutics 2010 Wei P, Walls M, Qiu M, Ding R, Denlinger RH, Wong A, Tsaparikos K, Jani JP, Hosea N, Sands M, Randolph S, Smeal T
• A forward genetic strategy reveals destabilizing mutations in the Ebolavirus glycoprotein that alter its protease dependence during cell entry.
  Journal of virology 2010 Wong AC, Sandesara RG, Mulherkar N, Whelan SP, Chandran K
• Drosophila hnRNP A1 homologs Hrp36/Hrp38 enhance U2-type versus U12-type splicing to regulate alternative splicing of the prospero twintron.
  Proceedings of the National Academy of Sciences of the United States of America 2009 Borah S, Wong AC, Steitz JA
• The c-Jun NH2-terminal kinase is essential for epidermal growth factor expression during epidermal morphogenesis.
  Proceedings of the National Academy of Sciences of the United States of America 2004 Weston CR, Wong A, Hall JP, Goad ME, Flavell RA, Davis RJ
• An intronic enhancer regulates splicing of the twintron of Drosophila melanogaster prospero pre-mRNA by two different spliceosomes.
  Molecular and cellular biology 2004 Scamborova P, Wong A, Steitz JA